Literature DB >> 20886558

Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.

Tokujiro Yano1, Akira Haro, Tsukihisa Yoshida, Yosuke Morodomi, Kensaku Ito, Yasunori Shikada, Fumihiro Shoji, Riichiroh Maruyama, Yoshihiko Maehara.   

Abstract

OBJECTIVES: In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
METHODS: From 1994 through 2004, 418 consecutive patients with NSCLC underwent complete resection; 138 experienced a postoperative recurrence by December 2005. Of those, we reviewed 93 patients with only distant metastases for clinicopathological information, treatment modality, and survival.
RESULTS: For the 93 patients with distant metastasis alone, the 2- and 5-year survival rates after recurrence were 43.9% and 38.7%, respectively. Of those patients, 44 first received local treatment, including radiotherapy in 31 and a surgical resection in 13. Their recurrent disease (oligometastases) was limited with the potential to be controlled with local treatment. The targeted metastatic organs were brain in 14 patients, bone in 14, lungs in 12, and other organs in 4. Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
CONCLUSION: Local therapy such as radiotherapy and surgery, might be considered first-line treatment in patients with postoperative oligometastatic recurrence, especially those with a DFI ≥ 1 year. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20886558     DOI: 10.1002/jso.21750

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  26 in total

1.  Prediction and prognostic factors of post-recurrence survival in recurred patients with early-stage NSCLC who underwent complete resection.

Authors:  Pil Jo Choi; Sang Seok Jeong; Sung Sil Yoon
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  Is there a benefit to locally consolidative therapy for oligometastatic non-small cell lung cancer?

Authors:  Lauren Boreta; Sue S Yom
Journal:  Ann Transl Med       Date:  2017-03

Review 3.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

4.  Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver.

Authors:  Fumitaka Ishige; Wataru Takayama; Satoshi Chiba; Isamu Hoshino; Hidehito Arimitsu; Hiroo Yanagibashi; Yosuke Iwatate
Journal:  Int J Clin Oncol       Date:  2018-03-06       Impact factor: 3.402

5.  Expanding the knowledge of oligometastatic disease-but uncertainties remain significant.

Authors:  Joachim Pfannschmidt
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  Accelerated radiotherapy and concurrent chemotherapy for patients with contralateral central or mediastinal lung cancer relapse after pneumonectomy.

Authors:  Christoph Pöttgen; Jehad Abu Jawad; Eleni Gkika; Lutz Freitag; Wolfgang Lübcke; Stefan Welter; Thomas Gauler; Martin Schuler; Wilfried Ernst Erich Eberhardt; Georgios Stamatis; Martin Stuschke
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

7.  Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.

Authors:  Jose Luis Lopez Guerra; Daniel Gomez; Yan Zhuang; David S Hong; John V Heymach; Stephen G Swisher; Steven H Lin; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-13       Impact factor: 7.038

8.  Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer.

Authors:  Tomoyoshi Takenaka; Eiko Inamasu; Tsukihisa Yoshida; Gouji Toyokawa; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Surg Today       Date:  2015-06-13       Impact factor: 2.549

9.  Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients.

Authors:  Makoto Sonobe; Masatsugu Hamaji; Hideki Motoyama; Toshi Menju; Akihiro Aoyama; Toyofumi F Chen-Yoshikawa; Toshihiko Sato; Hiroshi Date
Journal:  Surg Today       Date:  2018-03-03       Impact factor: 2.549

Review 10.  Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer.

Authors:  Tokujiro Yano; Tatsuro Okamoto; Seiichi Fukuyama; Yoshihiko Maehara
Journal:  World J Clin Oncol       Date:  2014-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.